Results 91 to 100 of about 113,281 (294)

Alogliptin: a new addition to the class of DPP-4 inhibitors

, 2009
Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the ...
Radha Andukuri, Andjela Drincic, Marc Rendell   +2 more
core  

Cost-effectiveness analysis of oral anti-diabetic medications: DPP-4 inhibitor as monotherapy vs. combination therapy in type 2 diabetic patients in Malang, Indonesia [PDF]

Background: Several anti-diabetic medications are covered under the Indonesian Universal Health Coverage (BPJS). However, metformin is typically prioritized over other options, such as DPP-4 inhibitors, because they are considered costly.
Sidek Ahmad, Zulkhairul Naim, Yurina, Valentina, Che Hasan, Muhammad Kamil, Oktaviana, Prita Aldilla, Triastuti, Efta   +4 more
core   +1 more source

Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy

Chemistry – A European Journal, EarlyView.
Integrin αVβ3‐targeting small‐molecule drug conjugates (SMDCs) were synthesized by conjugating a cryptophycin payload through a neutrophil elastase‐cleavable NPV‐PABC linker. RGD peptidomimetic and linker epimers served as controls for targeting and enzymatic cleavage, and the resulting conjugates displayed subnanomolar cytotoxicity in vitro.
Dominic Seißenschmidt, Henriette Hartung, Jonah Kammer, Norbert Sewald   +3 more
wiley   +1 more source

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

, 2019
Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice ...
Toshihiko Yanase, Ryoko Motonaga, Takashi Fukuda, Takashi Nomiyama, Takeshi Horikawa, Yuriko Hamaguchi, Tomoko Tanaka, Makito Tanabe, Yuichi Terawaki, Hiroyuki Takahashi, Takako Kawanami   +10 more
core   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Robinow syndrome DVL1 variants disrupt morphogenesis and appendage formation in a Drosophila disease model

Developmental Dynamics, EarlyView.
Abstract Background Robinow syndrome is a rare developmental syndrome caused by variants in genes in Wnt signaling pathways. We previously showed that expression of patient variants in Dishevelled 1 (DVL1) in Drosophila and chicken models disrupts the balance of canonical and non‐canonical Wnt signaling.
Gamze Akarsu, Katja R. MacCharles, Kenneth Kin Lam Wong, Joy M. Richman, Esther M. Verheyen   +4 more
wiley   +1 more source

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS

, 2016
Diabetes mellitus (DM) is a chronic disease which caused around 1.5 million deaths in 2012. Type 2 diabetes mellitus (T2DM) accounts for 90% of DM worldwide. The prevalence of T2DM is increasing due to obesity.
Kristin, Erna
core   +1 more source

Photodynamic Biomimetic Nanoparticles Accelerate Tumor Vascular Normalization Initiation

Exploration, EarlyView.
Platelet‐mimetic IA@PM integrates apatinib‐driven vascular normalization with ICG‐mediated photodynamic therapy, creating a self‐amplifying vascular normalization therapy (VNT)–photodynamic therapy (PDT) cycle that accelerates the onset of the vascular normalization window and potentiates antitumor treatment.
Yufei Liu, Changheng Xie, Yanfeng Huang, Ting Wang, Shi Du, Hui Xiong, Jing Yao   +6 more
wiley   +1 more source

Lactobacilli possess inhibitory activity against dipeptidyl peptidase-4 (DPP-4)

, 2015
Dipeptidyl peptidase 4 (DPP-4) enzymatically inactivates incretin hormones, and DPP-4 inhibitor drugs are clinically approved therapies for type 2 diabetes.
Panwar, Harsh, Calderwood, Danielle, Green, Brian D., Grover, Sunita, Grant, Irene R.; id_orcid   +4 more
core   +1 more source